Library Item - Page 35 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Comparing tibial nerve stimulation and antimuscarinic agents for the treatment of overactive bladder syndrome.

Comparing tibial nerve stimulation and antimuscarinic agents for the treatment of overactive bladder syndrome.

Posted by on Jan 16, 2022 in Overactive bladder | 0 comments

In a nutshell This study compared the effectiveness and safety of tibial nerve stimulation (TNS) versus antimuscarinic agents for the treatment of patients with overactive bladder (OAB). The study found that TNS was safer and as effective as antimuscarinic agents for the treatment of OAB. Some background Overactive bladder (OAB) occurs when the...

Read More

Do combination therapies given in fixed-doses polypills with aspirin reduce the risk of cardiovascular disease events?

Do combination therapies given in fixed-doses polypills with aspirin reduce the risk of cardiovascular disease events?

Posted by on Jan 16, 2022 in Hypertension | 0 comments

In a nutshell This study investigated whether a combination pill given in fixed doses with or without aspirin can reduce the risk of cardiovascular disease events in patients without a previous history of cardiovascular disease. The data showed that a fixed-dose combination treatment strategy with aspirin significantly reduced the risks of...

Read More

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Posted by on Jan 16, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC). The data showed that alectinib (Alecensa) and lorlatinib (Lorbrena) were the most effective and safest first-line treatment options for these patients. Some background...

Read More

Evaluating the effectiveness of adding immunotherapy to chemotherapy for metastatic triple-negative breast cancer.

Evaluating the effectiveness of adding immunotherapy to chemotherapy for metastatic triple-negative breast cancer.

Posted by on Jan 9, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of adding immunotherapy (IT) to chemotherapy (CT) for the treatment of patients with metastatic triple-negative breast cancer (TNBC). The data showed that the addition of IT to CT significantly improved survival without cancer worsening. However, IT plus CT combination did not...

Read More

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Posted by on Jan 9, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities) can be found in...

Read More

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Posted by on Jan 9, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities)...

Read More

Evaluating the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer.

Evaluating the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer.

Posted by on Jan 9, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR (epidermal growth factor receptor) plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with 5-fluorouracil...

Read More

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Posted by on Dec 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study assessed patient responses to focal thermo-ablative therapy (FTA) for oligo-recurrent prostate cancer (PCa) after pelvic radiotherapy. The data suggested that FTA therapy is a good option in these patients. Some background Oligometastatic PCa means that cancer has spread to only a few places (up to 5 metastases). It...

Read More

Comparing amphilimus and zotarolimus-eluting stents in patients with diabetes and coronary heart disease.

Comparing amphilimus and zotarolimus-eluting stents in patients with diabetes and coronary heart disease.

Posted by on Dec 31, 2021 in Coronary artery disease | 0 comments

In a nutshell This study compared Cre8 EVO (amphilimus-eluting) stents to Resolute Onyx (zotarolimus-eluting) stents in patients with diabetes and CAD undergoing percutaneous coronary intervention (PCI). The authors concluded that Cre8 EVO stents were similar or better than Resolute Onyx stents in these patients. Some background...

Read More

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

Posted by on Dec 31, 2021 in Diabetes mellitus | 0 comments

In a nutshell This review assessed the risk of hypoglycemia (dangerously low blood glucose) with the addition of sodium-glucose co-transporter 2 (SGLT-2) inhibitors to sulfonylureas in patients with type 2 diabetes (T2D). The authors concluded that this combination was associated with an increased risk of hypoglycemia. Some background...

Read More

Is AADC gene therapy a valuable option for patients with moderately advanced Parkinson Disease?

Is AADC gene therapy a valuable option for patients with moderately advanced Parkinson Disease?

Posted by on Dec 31, 2021 in Parkinson's Disease | 0 comments

In a nutshell In this work, the authors studied whether VY-AADC01 (NBIb-1817) gene therapy was safe and effective in patients with moderately advanced Parkinson's disease (PD) patients with motor fluctuations. The authors showed that this treatment caused an improvement in motor function, quality of life, and a decrease in the level of...

Read More

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Posted by on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate minimal residual disease (MRD) and long-term outcomes of patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (Venclexta) and obinutuzumab (Gazyva).  This study concluded that this treatment leads to an effective MRD reduction and has...

Read More